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chloride with lisinopril (major), furosemid with digoxin (moder-
ate), and warfarin with levoﬂoxacin (moderate). CONCLU-
SIONS: Potential DDIs were common in this elderly population
with multiple comorbidities. While some drug combinations
with potential DDIs may be clinically appropriate, they require
ongoing monitoring to ensure patient safety. The large number of
potential DDIs identiﬁed with these data warrants future research
into the prevalence of appropriate monitoring when potentially
interacting drug combinations are prescribed. This study demon-
strates the utility of using prescription claims databases for
identifying speciﬁc sub-populations of patients at high risk for
potential DDIs and targeting appropriate areas for intervention.
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OBJECTIVES: Heart attack is diagnosed in approximately
20000 cases annually in Hungary, half of which leads to death in
one year. In our study we investigated, how meteorological
factors inﬂuence the ﬁgures of heart attack, whether there is a
parallel relatonship between weather fronts and heart attack
during the study period. METHODS: We analyzed data of
patients admitted to hospitals in Hungary between 2000 and
2004, with the diagnosis of heart attack. During the study period
81,956 cases were recorded. We categorized patient subgroups
based on the day, month and year of the admission, and the
gender and age of the patients. The National Health Insurance
Fund and the National Weather Service provided us with the
appropriate data. Statistical analysis was performed using
ANOVA and chi2-probe. RESULTS: During the study period we
found a correlation between the incidence of heart attack cases
and meteorological factors. In spring, we observed signiﬁcantly
more heart attacks than in other seasons (p < 0.01). Cold
weather fronts in spring and summer positively correlated with
heart attack incidence, while in autumn and winter the warm
front had similar impact (p < 0.01). In 2002, there was a statis-
tically signiﬁcant difference between age groups below and above
50 years (p:0.069 vs. p:0.930, correspondingly). CONCLU-
SIONS: There is a statistically signiﬁcant seasonality in heart
attack incidence. The development of new prevention strategies
must rely on the seasonal and age characteristics of the change of
heart attack incidence throughout the world.
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OBJECTIVES: We investigated, wheter environmental tempera-
ture and workdays, beyond the well known risk factors, might
have an impact on the ﬁgures of heart attack cases in Hungary.
METHODS: Data analysis and retrospective data collection was
used among patients diagnosed with heart attack at the Cardiol-
ogy Department of the University of Pecs, Hungary in the time
period between January 1, 2000 andDecember 31, 2004.Weather
data were obtained from the Local Service of the National
Weather Institute, Pecs, Pogany Airport Base. In the time period
under investigation, 81.956 patientswere admittedwith the above
diagnosis. Analysis of variance and linear regression analysis were
used as statistical methods. RESULTS: We found that the envi-
ronmental temperature inﬂuenced the incidence of heart attack in
0.79 %. This result was found to be signiﬁcant (p < 0.01). Above
0 Co there were more heart attack cases diagnosed than below it.
We observed a steady decrease in the incidence from Monday to
weekend. Duringweekend daysmarkedly less caseswere recorded
comparing to weekdays (p: 0.110 MT[0.108;0.112] vs. p: 0.155
MT[0.153;0.158], respectively). Furthermore, there was a peak in
the number of cases on Monday and a drop during the weekend.
CONCLUSIONS:Environmental temperature has an effect on the
change in ﬁgures of heart attack cases, thus, we believe, it plays an
important rople in the disease.
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OBJECTIVES: The time of onset of a myocardial infarction
shows seasonal and daily variation. We aimed to investigate
whether the number of hours with daylight has an effect on the
seasonal variation of heart attack, and whether the time of
sunrise has an effect on the diurnal rhythm of myocardial infarc-
tion. METHODS: We carried out a retrospective database study
covering all patients admitted to any acute care hospital with the
diagnose of myocardial infarction in Hungary in years 2004 and
2005 (n = 32.329). Data was collected from the database of the
National Health Insurance Fund Administration according to the
International Classiﬁcation of Diseases (ICD). Data on the time
of sunrise and sunset was collected from the Hungarian National
Meteorological Service. RESULTS: With consideration to sea-
sonal variation, the peak period of a heart attack was found
during the spring season, with lowest number of events during
the months of summer. The number of hours with daylight
showed a weak negative correlation with the occurrence of myo-
cardial infarction (r = -0.108, p < 0.05). With consideration to
diurnal variation, the peak period of daily events was between
6–12 in the morning (35.57 %). We have found a positive cor-
relation between the time of sunrise and sunset and the occur-
rence of myocardial infarction (p < 0.01). CONCLUSIONS:
Based on our ﬁndings, the number of hours with daylight and the
time of sunrise may be connected with the chances of having a
heart attack, however other factors may also have an inﬂuence.
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OBJECTIVES:To predict total 3-year cardiovascular event (CVE)
rates for treatment with fenoﬁbric acid in combination with
statins versus statin monotherapy in a cohort of dyslipidemia
patients. METHODS: A disease outcomes model was used to
predict 3-year CVE rates in a cohort of 1000 dsylipidemia
patients. Risk of primary and secondary CVEs (MI, stroke,
angina) was based on published risk equations from the Framing-
ham Heart Study, which were adjusted to incorporate the impact
of triglycerides (TG) in addition to high-density lipoprotein cho-
lesterol and total cholesterol. The impact of TG was based on
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hazard ratios from a large trial with up to 28 years of follow-up
(Nordestgaard et al. 2007). This analysis used baseline lipid
proﬁle and lipid efﬁcacy data from three 12-week fenoﬁbric acid
(FA)/statin studies, where FA 135 mg combinedwith atorvastatin,
rosuvastatin, and simvastatin at low (20 mg, 10 mg, 20 mg,
respectively) and moderate (40 mg, 20 mg, 40 mg, respectively)
doses was compared to FA and corresponding statinmonotherapy
doses. RESULTS: Compared to statin monotherapy, combination
of FA 135 mg with low-dose simvastatin, rosuvastatin and ator-
vastatin was predicted to reduce 3-year CVE rates by 30% (from
35 to 27 events), 32% (from 33 to 25), and 33% (from 40 to 27),
respectively. Predicted 3-year CVE reductions were 15% to 21%
for FA in combination with a moderate-dose statin compared to
corresponding statin monotherapy. CONCLUSIONS: Patients
with multiple lipid abnormalities may require additional treat-
ment beyond statin monotherapy to address their dyslipidemia.
This analysis suggests that treatment with FA 135 mg in combi-
nation with a statin may result in a greater reduction in CVEs than
treatment with statin monotherapy.
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OBJECTIVES: Several reports have already proved that the
number of deaths related to acute myocardial infarction (AMI)
shows a seasonal variation, with a peak in winter, and a lowest
rates during the months of summer. The effects of meteorological
variables on the human organism have been studied for more
than ﬁfty years, and changes in the number of AMI events have
been related to both cold or warm temperatures. METHODS:
The number of cardiac mortality (N = 16.160) in Hungary shows
a steadily decreasing tendency between 2000 and 2005, with a
seasonal variation regardless of age or sex. RESULTS: The peak
period of AMI mortality was during the months of spring, with
a lowest value during the summer. There was a signiﬁcant differ-
ence between seasons (F = 3.027; p < 0.05). The daily average of
cardiovascular mortality during each season was the following:
8.48 during spring, 7.23 during the summer, 7.79 during
autumn, and 7.76 during winter. The sharp temperature increase
during spring, and the similarly signiﬁcant decrease of tempera-
tures during autumn, both have an increasing effect on heart
attack related mortality. Studying the moving-average of AMI
mortality (k = 7), and the relation with the daily average tem-
perature of the preceding 7 days, we have found a medium value
negative correlation (r = -0.466, p < 0.01). Considering the
moving average of deaths (k = 7) and the average daily tempera-
ture of the preceding seven days above and below 20 Celsius, we
have found a signiﬁcant difference. CONCLUSIONS: The mor-
tality of AMI may be related to the internal biological rhythm of
the organism, and also to such external conditions as weather.
The combined effect of certain meteorological factors, such as a
sudden temperature or atmospheric pressure change, may be
considered as a risk factor in the mortality of a heart attack.
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OBJECTIVES: To compare the tolerability of rosuvastatin 40 mg
with 20 mg in the treatment of patients with hypercholestero-
laemia based on a meta-analysis of 9 randomised controlled trials
(n = 3314) from the CRESTOR clinical trial programme.
METHODS: Data were extracted on the following organ
systems: Muscle (rhabdomyolysis, myopathy, myalgia, creatine
kinase increase); Liver (liver failure, hepatitis, abnormal liver
function [ALT increase]); Renal (renal failure, serum creatinine
increase, haematuria, proteinuria). The events analysed were all
treatment-emergent adverse events rather than treatment-related
adverse events to provide an objective evaluation of any possible
difference in risk between rosuvastatin 40 mg and 20 mg.
Summary effect estimates were calculated as risk difference (RD)
in meta-analyses using a ﬁxed effects model. RD is an absolute
measure of the difference in tolerability, i.e. percentages reported
are the risk of an event with rosuvastatin 40 mg compared to
20 mg (positive values indicate higher, negative values lower).
RESULTS: The event rates were low for all outcomes. For rhab-
domyolysis, liver failure, and hepatitis there were no events
with either rosuvastatin 40 mg or 20 mg. Other outcomes had
the following results—Muscle: myopathy 0.006% (95%CI:
-0.266% to 0.279%, p = 0.963), myalgia 0.216% (95%CI:
-0.874% to 1.306%, p = 0.697), creatine kinase increase
0.424% (95%CI: -0.099% to 0.947%, p = 0.112); Liver: abnor-
mal liver function 0.189% (95%CI: -0.415% to 0.793%,
p = 0.540); Renal: renal failure -0.023% (95%CI: -0.296% to
0.251%, p = 0.871), serum creatinine increase 0.033% (95%CI:
-0.239% to 0.305%, p = 0.811), haematuria -0.015%
(95%CI: -0.372% to 0.342%, p = 0.936), proteinuria 0.070%
(95%CI: -0.274% to 0.415%, p = 0.689). Sensitivity analysis,
using random effects model, demonstrated no difference in any of
the outcomes except myalgia, for which there was a small
numerical difference (0.420%; 95%CI: -1.332% to 2.172%;
p = 0.638). CONCLUSIONS: There is no evidence from ran-
domised controlled trials to suggest any difference in tolerability
between rosuvastatin 40 mg and 20 mg.
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